SHCBP1 and cancer: From a therapeutic standpoint, genetic or pharmacological inhibition of SHCBP1 through RNAi, CRISPR-mediated editing, or modulation of its upstream regulatory factors has produced strong anti-cancer effects in various preclinical models.